Beatriz Oliveira

Ms. Beatriz Oliveira

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2022 in WIREs Nanomedicine and Nanobiotechnology
Verified
Journal Article
Closed access
BOBeatriz Oliveira
Beatriz Oliveira
DFDaniela Ferreira
Daniela Ferreira
AFAlexandra R. Fernandes
Alexandra R. Fernandes
Pedro BaptistaPedro Baptista
Pedro Baptista

26 November 2024 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
PDF file
SCSandra Cordeiro
Sandra Cordeiro
BOBeatriz Oliveira
Beatriz Oliveira
RVRuben Valente
Ruben Valente
DFDaniela Ferreira
Daniela Ferreira
ALAndré Luz
André Luz
Alexandra FernandesAlexandra Fernandes
Alexandra Fernandes
Despite extensive efforts to unravel tumor behavior and develop anticancer therapies, most treatments fail when advanced to clinical trials. The main challenge in cancer research has been the absence of predictive cancer models, accurately mimicking the tumoral processes and response to treatments. The tumor microenvironment (TME) shows several human-specific physical and chemical properties, which cannot be fully recapitulated by the conventional 2D cell cultures or the in vivo animal models. These limitations have driven the development of novel in vitro cancer models, that get one step closer to the typical features of in vivo systems while showing better species relevance. This review introduces the main considerations required for developing and exploiting tumor spheroids and organoids as cancer models. We also detailed their applications in drug screening and personalized medicine. Further, we show the transition of these models into novel microfluidic platforms, for improved control over physiological parameters and high-throughput screening. 3D culture models have provided key insights into tumor biology, more closely resembling the in vivo TME and tumor characteristics, while enabling the development of more reliable and precise anticancer therapies.

14 March 2020 in Sensors
Verified
Journal Article
Open access
PDF file
BOBeatriz Oliveira
Beatriz Oliveira
BVBruno Veigas
Bruno Veigas
Alexandra FernandesAlexandra Fernandes
Alexandra Fernandes
Hugo ÁguasHugo Águas
Hugo Águas
Rodrigo MartinsRodrigo Martins
Rodrigo Martins
Pedro BaptistaPedro Baptista
Pedro Baptista
Microfluidic (MF) advancements have been leveraged toward the development of state-of-the-art platforms for molecular diagnostics, where isothermal amplification schemes allow for further simplification of DNA detection and quantification protocols. The MF integration with loop-mediated isothermal amplification (LAMP) is today the focus of a new generation of chip-based devices for molecular detection, aiming at fast and automated nucleic acid analysis. Here, we combined MF with droplet digital LAMP (ddLAMP) on an all-in-one device that allows for droplet generation, target amplification, and absolute quantification. This multilayer 3D chip was developed in less than 30 minutes by using a low-cost and extremely adaptable production process that exploits direct laser writing technology in “Shrinky-dinks” polystyrene sheets. ddLAMP and target quantification were performed directly on-chip, showing a high correlation between target concentration and positive droplet score. We validated this integrated chip via the amplification of targets ranging from five to 500,000 copies/reaction. Furthermore, on-chip amplification was performed in a 10 µL volume, attaining a limit of detection of five copies/µL under 60 min. This technology was applied to quantify a cancer biomarker, c-MYC, but it can be further extended to any other disease biomarker.

10 March 2026 in Revista Psicologia e Saúde
Verified
Journal Article
Open access
PDF file
ASAna Karla Silva Soares
Ana Karla Silva Soares
RCRenata Tereza dos Passos Costa
Renata Tereza dos Passos Costa
ESElin Nogueira Santos
Elin Nogueira Santos
LFLaura Pires Ferreira
Laura Pires Ferreira
BOBeatriz Oliveira
Beatriz Oliveira
O otimismo é reconhecido por exercer um papel fundamental na experiência humana, contribuindo para níveis mais elevados de bem-estar, maior realização de metas e uma melhor condição de saúde. Apesar de questionamentos sobre expectativas futuras serem direcionados a crianças, são escassos na literatura estudos sobre essa temática com este público. Assim, o presente estudo busca avaliar o papel da personalidade na compreensão da visão otimista das crianças frente ao futuro. Participaram 406 crianças, com idade média de 10 anos (8 a 12 anos; DP = 1,10), a maioria do sexo feminino (56,3%), de escola pública (34,2%). Estes responderam à Escala de Perspectiva de Futuro Infantil, ao Questionário de Cinco Fatores para Crianças e a questões sociodemográficas. Os resultados indicam uma correlação positiva e significativa do otimismo frente ao futuro com agradabilidade (r = 0,30), conscienciosidade (r = 0,35), extroversão (r = 0,17) e abertura à mudança (r = 0,28), contudo, somente conscienciosidade (β = 0,27) e agradabilidade (β = 0,28) predizem a visão otimista das crianças [R² = 0,15]. Conclui-se que entender os traços de personalidade de crianças oferece insights sobre suas visões de futuro, que favorecem intervenções, orientando um crescimento mais saudável.

21 October 2024 in Cancers
Verified
Journal Article
Open access
PDF file
ABAna Catarina Bravo
Ana Catarina Bravo
BMBárbara Morão
Bárbara Morão
ALAndré Luz
André Luz
RDRúben Dourado
Rúben Dourado
BOBeatriz Oliveira
Beatriz Oliveira
MCMarília Cravo
Marília Cravo
Background/Objectives: Pancreatic ductal adenocarcinoma (PDAC) incidence is rising, and prognosis remains poor due to late diagnosis and limited effective therapies. Currently, patients are treated based on TNM staging, without molecular tumor characterization. This study aimed to validate a technique that combines the amplification refractory mutation system (ARMS) with high-resolution melting analysis (HRMA) for detecting mutations in codon 12 of KRAS in tumor and plasma, and to assess its prognostic value. Methods: Prospective study including patients with newly diagnosed PDAC with tumor and plasma samples collected before treatment. Mutations in codon 12 of KRAS (G12D, G12V, G12C, and G12R) were detected using ARMS–HRMA and compared to Sanger sequencing (SS). Univariate and multivariate analyses were used to evaluate the prognostic significance of these mutations. Results: A total of 88 patients, 93% with ECOG-PS 0–1, 57% with resectable disease. ARMS–HRMA technique showed a higher sensitivity than SS, both in tumor and plasma (77% vs. 51%; 25 vs. 0%, respectively). The most frequent mutation was G12D (n = 32, 36%), followed by G12V (n = 22, 25%). On multivariate analysis, patients with G12D and/or G12C mutations, either in tumor or plasma, had lower PFS (HR 1.792, 95% CI 1.061–3.028, p = 0.029; HR 2.081, 95% CI 1.014–4.272, p = 0.046, respectively) and lower OS (HR 1.757, 95% CI 1.013–3.049, p = 0.045; HR 2.229, 95% CI 1.082–4.594, p = 0.030, respectively). Conclusions: ARMS–HRMA is a rapid and cost-effective method for detecting KRAS mutations in PDAC patients, offering the potential for stratifying prognosis and guiding treatment decisions. The presence of G12D and G12C mutations in both tumor and plasma is associated with a poorer prognosis.